Emerging Allosteric Mechanism of EGFR Activation in Physiological and Pathological Contexts

Protein kinases are key players in signal transduction pathways where they are crafted into two functional states. In response to growth factor binding stimulus, epidermal growth factor receptor (EGFR), which is physiologically populated in an autoinhibited inactive state, becomes active. Here, we outline a simple allostery scheme to clarify how an extracellular (ligand-dependent) binding event activates the intracellular EGFR kinase domain via (dimer-dependent) asymmetric dimerization, as well as how pathologically overexpressed EGFR or constitutively active mutants, leads to oncogenic pathway activation. Our underlying allosteric activation mechanism derives from a collection of inactive versus active EGFR structural, biochemical (negatively cooperative ligand binding), and biophysical (weak coupling between extracellular and intracellular kinase dimerization) data. The emerging structural insight reveals that ligand-dependent physiological activation is an outside-in allosteric activation with strong structural coupling across the membrane. In contrast, ligand-independent pathological activation is a weak inside-out activation mediated by intracellular kinase dimerization, which is structurally accommodated by additional extracellular dimers.

[1]  R. Nussinov,et al.  'Latent drivers' expand the cancer mutational landscape. , 2015, Current opinion in structural biology.

[2]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[3]  M. Lemmon,et al.  Ligand regulation of a constitutively dimeric EGF receptor , 2015, Nature Communications.

[4]  D. Shaw,et al.  Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor , 2013, Cell.

[5]  R. Gniadecki,et al.  Ligand-independent activation of the EGFR by lipid raft disruption. , 2006, The Journal of investigative dermatology.

[6]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[7]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[8]  John G. Koland,et al.  Coarse-Grained Molecular Simulation of Epidermal Growth Factor Receptor Protein Tyrosine Kinase Multi-Site Self-Phosphorylation , 2014, PLoS Comput. Biol..

[9]  Ozlem Keskin,et al.  Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation , 2015, Expert review of proteomics.

[10]  Y. Sako,et al.  Lipid-Protein Interplay in Dimerization of Juxtamembrane Domains of Epidermal Growth Factor Receptor. , 2018, Biophysical journal.

[11]  L. Pike,et al.  The Membrane-proximal Intracellular Domain of the Epidermal Growth Factor Receptor Underlies Negative Cooperativity in Ligand Binding* , 2011, The Journal of Biological Chemistry.

[12]  A. Pozzi,et al.  The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.

[13]  T. Walz,et al.  Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor* , 2012, The Journal of Biological Chemistry.

[14]  A. Ullrich,et al.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.

[15]  Anton Arkhipov,et al.  Architecture and Membrane Interactions of the EGF Receptor , 2013, Cell.

[16]  M. Lemmon,et al.  Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor , 2010, Cell.

[17]  R. Nussinov,et al.  Unraveling structural mechanisms of allosteric drug action. , 2014, Trends in pharmacological sciences.

[18]  S. Harrison,et al.  Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes , 1996, Nature Structural Biology.

[19]  Ruth Nussinov,et al.  A Unified View of “How Allostery Works” , 2014, PLoS Comput. Biol..

[20]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[21]  L. Pike,et al.  The Tethering Arm of the EGF Receptor Is Required for Negative Cooperativity and Signal Transduction* , 2010, The Journal of Biological Chemistry.

[22]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[23]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[24]  Anatoly Kiyatkin,et al.  The Dark Side of Cell Signaling: Positive Roles for Negative Regulators , 2016, Cell.

[25]  M. Resh,et al.  Cholesterol Depletion from the Plasma Membrane Triggers Ligand-independent Activation of the Epidermal Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[26]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[27]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[28]  John Foley,et al.  Functional selectivity of EGF family peptide growth factors: implications for cancer. , 2009, Pharmacology & therapeutics.

[29]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[30]  E. Isacoff,et al.  Molecular basis for multimerization in the activation of the epidermal growth factor receptor , 2016, eLife.

[31]  A. Kiyatkin,et al.  EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics , 2017, Cell.

[32]  Ruth Nussinov,et al.  Precision medicine review: rare driver mutations and their biophysical classification , 2019, Biophysical Reviews.

[33]  Laura C. Zanetti-Domingues,et al.  The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers , 2018, Nature Communications.

[34]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[35]  G. Kéri,et al.  Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. , 2015, Cancer cell.

[36]  S. Skvortsov,et al.  Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network , 2008, Proteomics.

[37]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[38]  Shigeyuki Yokoyama,et al.  Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor , 2010, Molecular and Cellular Biology.

[39]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.